Investigation of fluconazole heteroresistance in clinical and environmental isolates of Cryptococcus neoformans complex and Cryptococcus gattii complex in the state of Amazonas, Brazil
Abstract
Heteroresistance, defined as the occurrence of apparently homogeneous subpopulations of microbial cells showing different levels of antimicrobial susceptibility is a problem that has been associated with therapeutical failure in cryptococcosis. The purpose of the study was an investigation on the level of heteroresistance to fluconazole (LHF) as observed in clinical and environmental C. neoformans/C. gattii complex species isolates from Amazonas State (AM), Brazil. A total of 45 isolates and 9 type strains were analyzed. The assessments comprised testing for minimal inhibitory concentrations (MICs), for LHFs, for the strains’ capacity of adaptation to high fluconazole (FLC) concentrations above the LHF, and for the stability of the heteroresistance phenomenon. The mean MICs for clinical isolates of C. gattii (6.4 µg/ml) were higher than those observed for environmental C. gattii strains (1.7 µg/ml) and clinical (3.7 µg/ml) as well as environmental (1.5 µg/ml) C. neoformans isolates. The phenomenon of heteroresistance to FLC was recorded for all isolates. On average, the LHF (8–256 µg/ml) of the isolates was 16 times higher than the FLC MICs (0.5–16 µg/ml) and a proportion of 85% isolates showed LHFs ≥ 16 µg/ml, 40% even ≥ 32 µg/ml. According to the adaptation assay, a considerable number of isolates (58%) showed the capacity of adaptation to MICs even higher than the initially recorded LHF. After the adaptation experiment, the adaptative-LHF values (8–512 µg/ml) were about 60 times higher than the original MIC values. After nine subsequent passages in drug-free broth, the isolates had their adaptative-LHF reduced. However, the LHF did not revert to the initially measured level. Our findings challenge the clinical interpretation of the antifungal MIC testing and motivate future studies correlating the levels of heteroresistance and parameters like LHF and adaptative-LHF with cryptococcosis-associated morbidity and mortality. Lay summary: Cryptococcosis affects many people and is caused by fungi of the Cryptococcus neoformans/Cryptococcus gattii complexes. These agents appear to become more resistant to antifungals when exposed to increasing concentrations of antifungals due to a phenomenon called heteroresistance.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Increased emergence of heteroresistance in clinical versus environmental isolates supports the induction effect of antifungal exposure.
“Several studies have confirmed the increased emergence of heteroresistance in clinical, compared with environmental, isolates, supporting the induction effect of antifungal exposure [101,158].”
From Insight into the Mechanisms and Clinical Relevance of Antifungal Heteroresistance (2025) · cites this paper as [158]
Several studies have confirmed increased emergence of heteroresistance in clinical compared with environmental isolates.
“Several studies have confirmed the increased emergence of heteroresistance in clinical, compared with environmental, isolates, supporting the induction effect of antifungal exposure [101,158].”
From Insight into the Mechanisms and Clinical Relevance of Antifungal Heteroresistance (2025) · cites this paper as [158]
Cites
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660 · see citing works
Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · see citing works
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 654 · see citing works
Antimicrobial heteroresistance: An emerging field in need of clarity
El-Halfawy, O. M., & Valvano, M. A. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-14 · Cited by 489 · see citing works
Sionov, E., Lee, H., Chang, Y. C., & Kwon-Chung, K. J. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000848 · Cited by 479 · see citing works
Bicanic, T. A., Harrison, T. S., Niepieklo, A., Dyakopu, N., & Meintjes, G. (2006) · Clinical Infectious Diseases · doi:10.1086/507895 · Cited by 222 · see citing works
Ancient dispersal of the human fungal pathogen Cryptococcus gattii from the Amazon rainforest
Hagen, F., Ceresini, P. C., Polacheck, I., Ma, H., Nieuwerburgh, F. V., Gabaldón, T., Kagan, S., Pursall, E. R., Hoogveld, H. L., van Iersel, L. J. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071148 · Cited by 218 · see citing works
Sionov, E., Chang, Y. C., Garraffo, H. M., & Kwon-Chung, K. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00295-09 · Cited by 179 · see citing works
Correlation of Fluconazole MICs with Clinical Outcome in Cryptococcal Infection
Aller, A. I., Martín‐Mazuelos, E., Lozano, F., Gómez-Mateos, J. M., Steele‐Moore, L., Holloway, W. J., Gutiérrez, M. J., Recio, F., & Espinel-Ingroff, A. V. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1544-1548.2000 · Cited by 171 · see citing works
Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis
Stone, N. R. H., Rhodes, J., Fisher, M. C., Mfinanga, S., Kivuyo, S., Rugemalila, J., Segal, E. S., Needleman, L., Molloy, S. F., Kwon-Chung, J., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124516 · Cited by 167 · see citing works
Marr, K. A., Lyons, C. N., Rustad, T., Bowden, R. A., & White, T. C. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2584 · Cited by 166 · see citing works
Mechanisms of heteroresistance in methicillin-resistant Staphylococcus aureus
Ryffel, C., Strässle, A., Kayser, F. H., & Berger‐Bächi, B. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.4.724 · Cited by 140 · see citing works
Heteroresistance to Fluconazole and Voriconazole in <i>Cryptococcus neoformans</i>
Mondon, P., Petter, R., Amalfitano, G., Luzzati, R., Concia, E., Polacheck, I., & Kwon-Chung, K. J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.8.1856 · Cited by 139 · see citing works
Witt, M. D., Lewis, R. J., Larsen, R. A., Milefchik, E. N., Leal, M. A. E., Haubrich, R., Richie, J., Edwards, J. E., & Ghannoum, M. A. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.2.322 · Cited by 136 · see citing works
Drug resistance in Cryptococcus neoformans
Perfect, J. R., & Cox, G. M. (1999) · Drug Resistance Updates · doi:10.1054/drup.1999.0090 · Cited by 106 · see citing works
Heteroresistance of <i>Cryptococcus gattii</i> to Fluconazole
Varma, A., & Kwon-Chung, K. J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00153-10 · Cited by 103 · see citing works
Dannaoui, É., Abdul, M., Arpin, M., Michel-Nguyen, A., Piens, M. A., Favel, A., Lortholary, O., Dromer, F., & the French Cryptococcosis Study Group (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01520-05 · Cited by 102 · see citing works
Hope, W., Stone, N. R. H., Johnson, A., McEntee, L., Farrington, N., Santoro-Castelazo, A., Liu, X., Lucaci, A., Hughes, M., Oliver, J. D., et al. (2019) · mBio · doi:10.1128/mbio.02575-19 · Cited by 70 · see citing works
Chang, M., Sionov, E., Lamichhane, A. K., Kwon-Chung, K. J., & Chang, Y. C. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01751-17 · Cited by 63 · see citing works
Yamazumi, T., Pfaller, M. A., Messer, S. A., Houston, A. K., Boyken, L., Hollis, R. J., Furuta, I., & Jones, R. N. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.1.267-272.2003 · Cited by 62 · see citing works
Hurtado, J. C., Castillo, P., Fernandes, F., Navarro, M., Lovane, L., Casas, I., Quintó, L., Marco, F., Jordão, D., Ismail, M. R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43941-w · Cited by 60 · see citing works
Heteroresistance to Vancomycin in Enterococcus faecium
Alam, M. R., Donabedian, S. M., Brown, W. J., et al. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.9.3379-3381.2001 · Cited by 40 · see citing works
Silva, B. K. D., Freire, A. K. L., Bentes, A. D. S., et al. (2011) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2011.05.003 · Cited by 34 · see citing works
Rocha, D. F. S., Cruz, K. S., Santos, C. S. D. S., Menescal, L. S. F., Neto, J. R. D. S., Pinheiro, S. B., Silva, L. M., Trilles, L., & de Souza, J. V. B. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197841 · Cited by 29 · see citing works
Self-citationNyazika, T. K., Tatuene, J. K., Kenfak-Foguena, A., Verweij, P. E., Meis, J. F. G. M., Robertson, V. J., & Hagen, F. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020654 · Cited by 26 · see citing works
Cryptococcal meningitis in non-HIV patients in the State of Amazonas, Northern Brazil
Pinheiro, S. B., de Sousa, N. S. O., Cortez, A. C. A., Rocha, D. F. S., Menescal, L. S. F., Chagas, V. S., Pérez-Gómez, A. S., Cruz, K. S., Santos, L. O., Alves, M. J., et al. (2020) · Brazilian Journal of Microbiology · doi:10.1007/s42770-020-00383-1 · Cited by 22 · see citing works
Self-citationLetang, E., Rakislova, N., Martínez, M. J., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab789 · Cited by 21 · see citing works
Cryptococcus gattii VGII isolated from native forest and river in Northern Brazil
Bentes, A. D. S., Wanke, B., Lazéra, M. D. S., et al. (2019) · Brazilian Journal of Microbiology · doi:10.1007/s42770-019-00066-6 · Cited by 19 · see citing works
Feliciano, L. M., Ramos, S. D. P., Szeszs, M. W., Martins, M. A., Bonfietti, L. X., de Oliveira, R. A., Santos, D. C. S., Fadul, L. H., Silva, D., Paula, C. R., et al. (2017) · Current Fungal Infection Reports · doi:10.1007/s12281-017-0298-1 · Cited by 4 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Beyond resistance: antifungal heteroresistance and antifungal tolerance in fungal pathogens
Yang, F., & Berman, J. (2024) · Current Opinion in Microbiology · doi:10.1016/j.mib.2024.102439 · Cited by 42 · see citing works
Insight into the Mechanisms and Clinical Relevance of Antifungal Heteroresistance
Su, Y., Li, Y., Yi, Q., Xu, Y., Sun, T., & Li, Y. (2025) · Journal of Fungi · doi:10.3390/jof11020143 · Cited by 18 · see citing works
“Several studies have confirmed the increased emergence of heteroresistance in clinical, compared with environmental, isolates, supporting the induction effect of antifungal exposure [101,158].”
- Authors
- Moreira, I. D. M. B., Cortez, A. C. A., de Souza, É. S., Pinheiro, S. B., de Souza Oliveira, J. G., Sadahiro, A., Cruz, K. S., Matsuura, A. B. J., Melhem, M. D. S. C., Frickmann, H., & de Souza, J. V. B.
- Affiliations
- Universidade Federal do Amazonas (BR)
- Instituto Nacional de Pesquisas da Amazônia (BR)
- Superior School of Technology, Amazon State University- UEA, 69050-020, Manaus, Brazil
- Collection of Microorganisms of Medical Interest, Coordination of Society, Environment and Health, National Institute for Amazonian Research- INPA, 69060-001, Manaus, Brazil
- Laboratory of Mycology, Tropical Medicine Foundation Dr. Heitor Vieira Dourado- FMT- HVD, 69040-000, Manaus, Brazil
- Fiocruz Amazônia (BR)
- Universidade Federal de Mato Grosso do Sul (BR)
- Bundeswehrkrankenhaus (DE)
- Laboratory of Mycology, Coordination of Society, Environment and Health, National Institute for Amazonian Research-INPA, 69060-001, Manaus, Brazil
- ORCID
- Venue
- Medical Mycology
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-01-27
- Volume
- 60
- Issue
- 3
- ISSN
- 0268-1218 (ISSN-L)
- 1369-3786
- 1460-2709
- OpenAlex
- W4206998595
- Cited by
- 22
- References
- 29
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 6 · 2023: 4 · 2022: 2
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Medical Mycology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Fundação de Amparo à Pesquisa do Estado do Amazonas (001/2017)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Topics
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
- Keywords
- cryptococcosis, antifungal susceptibility, minimum inhibitory concentration, clinical isolates, environmental isolates, Amazonas, type strain
- MeSH terms
- Animals, Antifungal Agents, Brazil, Cryptococcosis, Cryptococcus neoformans, Microbial Sensitivity Tests, Fluconazole, Drug Resistance, Fungal, Cryptococcus gattii
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review